Tags Color
#87BCDE

Amarin Chairman & CEO Issue Letter to Shareholders

Submitted by amarin on Mon, 01/22/2024 - 12:30
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Chairman of the Board, Odysseas Kostas, M.D., and President & CEO, Patrick Holt, issued the following letter to Amarin shareholders: Dear Fellow Amarin

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

Submitted by amarin on Wed, 01/10/2024 - 12:00
-- Reported Unaudited Total Revenues of Between $72 Million - $74 Million in the Fourth Quarter of 2023 -- -- Company Ends 2023 with a Cash Position of $321 Million and Delivered Full-Year Positive Cash Flow of ~$10 Million -- -- 2024 Key Priorities Include Accelerating Revenue in Key European

Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Submitted by amarin on Mon, 12/11/2023 - 13:01
DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its participation in the 42 nd Annual JP Morgan Healthcare Conference. Amarin’s president and chief executive officer, Patrick Holt, is scheduled to present at the

Amarin Reports Third Quarter 2023 Financial Results

Submitted by amarin on Wed, 11/01/2023 - 11:01
-- Company Reported Total Net Revenues of $66 Million in the Third Quarter 2023 -- -- Delivered Positive Cash Flow of $8 Million in the Quarter, Marking Fifth Consecutive Quarter of Cash Positive Operations 1 ; Quarter-Ending Cash Position of $321 Million -- -- Company Continues to Deliver

Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer

Submitted by amarin on Tue, 10/31/2023 - 16:00
-- Provoost Brings More than 20 Years of Corporate Counsel Experience to Amarin -- DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Jonathan Provoost as the Company's new Executive Vice President, Chief

Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023

Submitted by amarin on Thu, 10/26/2023 - 12:00
-- Additional Mechanistic Data on Eicosapentaenoic Acid (EPA) and Real-World Characteristics of Patients with Diabetes on IPE Also Featured at the Meeting -- DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported

 Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023

Submitted by amarin on Thu, 10/19/2023 - 12:01
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss the Company’s third quarter 2023 financial

Amarin to Present at the 2023 Cantor Global Healthcare Conference

Submitted by amarin on Tue, 09/12/2023 - 12:01
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer, is scheduled to participate via fireside chat at the 2023 Cantor Global Healthcare Conference.

Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy

Submitted by amarin on Wed, 08/09/2023 - 20:06
– Dutch Ministry of Health Approves VAZKEPA ® (icosapent ethyl) for National Reimbursement to Reduce the Risk of Cardiovascular Events in Patients with Established Cardiovascular Disease – – Italy’s AIFA Pricing & Reimbursement Committee (CPR) Issues Negative Decision on VAZKEPA; Follows Positive